Research programme: orexin 1 inhibitors - Evotec

Drug Profile

Research programme: orexin 1 inhibitors - Evotec

Alternative Names: Orexin 1 antagonist - Evotec

Latest Information Update: 17 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Evotec AG
  • Developer C4X Discovery; Evotec AG
  • Class
  • Mechanism of Action Orexin receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug abuse

Highest Development Phases

  • Preclinical Drug abuse

Most Recent Events

  • 06 Oct 2016 Research programme: orexin 1 inhibitors - Evotec is available for licensing as of 06 Oct 2016. www.c4xdiscovery.com
  • 12 Jul 2016 C4X Discovery Holdings acquires drug discovery technologies from from MolPlex Ltd
  • 05 Apr 2016 C4X Discovery plans a phase I trial for Drug abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top